Trial Profile
A retrospective, multicenter study of Melphalan/HDS in patients with ocular melanoma metastasized to the liver
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2017
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Therapeutic Use
- 03 Mar 2017 New trial record
- 21 Feb 2017 According to Delcath Systems media release, the findings were reported at the Regional Cancer Therapies 12th International Symposium in an oral presentation. The presentation was led by Dr. Alexandra Gangi of the Moffitt Cancer Center.
- 21 Feb 2017 According to Delcath Systems media release, patients treated at either the Moffitt Cancer Center or the University Hospital Southampton.